Table 1 Baseline characteristics and outcomes at baseline and 6-month follow-up

From: No evidence for an association of voxel-based morphometry with short-term non-motor outcomes in deep brain stimulation for Parkinson’s disease

 

N

M

SD

     

Age [y]

49

64.47

8.23

     

Disease duration [y]

49

9.99

4.35

     

Sex (female/male) [%]

49

18/31

[36.7/63.3]

     
 

Baseline

6-MFU

Baseline vs. 6-MFU

 

n

M

SD

n

M

SD

p

Cohen’s d

NMSS-total score

49

51.1

25.2

49

39.2

26.3

0.003

0.46

 Cardiovascular

49

1.8

3.0

49

1.4

2.0

0.656

0.13

 Sleep/fatigue

49

13.2

9.1

49

9.0

5.9

0.001

0.55

 Mood/apathy

49

5.3

5.7

49

6.6

12.1

0.409

−0.13

 Perceptual problems /hallucinations

49

1.9

3.9

49

0.7

2.1

0.012

0.39

 Attention/memory

49

4.6

4.8

49

3.7

4.1

0.201

0.20

 Gastrointestinal

49

4.3

4.6

49

5.0

5.8

0.733

−0.12

 Urinary

49

9.8

8.9

49

6.9

7.2

0.015

0.35

 Sexual function

49

2.3

4.0

49

1.6

2.9

0.111

0.21

 Miscellaneous

49

8.1

6.5

49

4.4

4.0

<0.001

0.68

PDQ-8 SI

43

33.0

16.3

48

24.9

14.5

<0.001

0.52

UPDRS-III

49

24.4

10.7

45

19.7

10.0

0.014

0.45

SCOPA-M activities of daily living

49

8.0

2.7

49

6.3

3.2

<0.001

0.56

SCOPA-M motor complications

49

4.0

2.8

45

1.8

2.3

<0.001

0.85

LEDD [mg]

49

1102

590.3

48

588.6

341.9

<0.001

1.06

  1. Demographic characteristics and outcome parameters at baseline and 6-month follow-up. Reported p values are corrected for multiple comparisons using Benjamini–Hochberg’s method (six main outcome scales). Bold font highlights significant results, p < 0.05.
  2. 6-MFU 6-month follow-up, LEDD levodopa equivalent daily dose, LEDD-DA LEDD of dopamine agonists, NMSS non-motor symptom scale, PDQ-8 SI 8-item Parkinson’s disease questionnaire summary index, SCOPA-M scales for outcomes in Parkinson’s disease-motor, SD standard deviation, UPDRS-III unified Parkinson’s disease rating scale part III.
Back to article page